Remove Bioinformatics Remove Engineering Remove Small Molecule
article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.

RNA 52
article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part II)

Practical Cheminformatics

No member company will agree to use a representation that can potentially be reverse-engineered to reveal the chemical structures of its molecules. In each example, the authors use a modified version of their open source package MolPAL to design molecules with a specified selectivity profile.

Drugs 141
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. There, I supported AI-enabled DD efforts in their small molecule portfolio. Bioinformatics is all about bringing together different areas of knowledge.

article thumbnail

AI-driven drug discovery: insights from Cresset

Drug Target Review

Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their small molecule discovery processes efficiently and effectively. He also held a genomics consultancy role and worked as an R&D engineer in the speech-to-text domain at Hewlett Packard.

Drugs 64
article thumbnail

Codon Digest: GPT-4 Controls a Robot

Codon

Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study.